Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
CMAJ. 2011 Apr 19;183(7):796-804. doi: 10.1503/cmaj.101063. Epub 2011 Apr 11.
The association between the risk of orofacial clefts in infants and the use of corticosteroids during pregnancy is unclear from the available evidence. We conducted a nationwide cohort study of all live births in Denmark over a 12-year period.
We collected data on all live births in Denmark from Jan. 1, 1996, to Sept. 30, 2008. We included live births for which information was available from nationwide health registries on the use of corticosteroids during pregnancy, the diagnosis of an orofacial cleft and possible confounders.
There were 832,636 live births during the study period. Exposure to corticosteroids during the first trimester occurred in 51,973 of the pregnancies. A total of 1232 isolated orofacial clefts (i.e., cleft lip, cleft palate, or cleft lip and cleft palate) were diagnosed within the first year of life, including 84 instances in which the infant had been exposed to corticosteroids during the first trimester of pregnancy. We did not identify any statistically significant increased risk of orofacial clefts associated with the use of corticosteroids: cleft lip with or without cleft palate, prevalence odds ratio (OR) 1.05 (95% confidence interval [CI] 0.80-1.38]; cleft palate alone, prevalence OR 1.23 (95% CI 0.83-1.82). Odds ratios for risk of orofacial clefts by method of delivery (i.e., oral, inhalant, nasal spray, or dermatologic and other topicals) were consistent with the overall results of the study and did not display significant heterogeneity, although the OR for cleft lip with or without cleft palate associated with the use of dermatologic corticosteroids was 1.45 (95% CI 1.03-2.05).
Our results add to the safety information on a class of drugs commonly used during pregnancy. Our study did not show an increased risk of orofacial clefts with the use of corticosteroids during pregnancy. Indepth investigation of the pattern of association between orofacial clefts and the use of dermatologic corticosteroids during pregnancy indicated that this result did not signify a causal connection and likely arose from multiple statistical comparisons.
现有证据表明,皮质类固醇在孕妇中的使用与婴儿唇腭裂风险之间的关联并不明确。我们对丹麦 12 年间的所有活产儿进行了全国性队列研究。
我们从 1996 年 1 月 1 日至 2008 年 9 月 30 日收集了丹麦所有活产儿的数据。我们纳入了来自全国健康登记处的关于皮质类固醇在怀孕期间的使用情况、唇腭裂的诊断以及可能的混杂因素的信息。
在研究期间,共有 832636 例活产儿。在妊娠的前三个月,有 51973 例暴露于皮质类固醇。在生命的第一年,共诊断出 1232 例孤立性唇腭裂(即唇裂、腭裂或唇裂和腭裂),其中 84 例婴儿在妊娠的前三个月暴露于皮质类固醇。我们没有发现皮质类固醇的使用与唇腭裂之间存在任何统计学意义上的风险增加:唇裂伴或不伴腭裂,患病率比值比(OR)为 1.05(95%置信区间[CI]0.80-1.38);单纯腭裂,患病率 OR 为 1.23(95%CI 0.83-1.82)。通过分娩方式(即口服、吸入、鼻喷或皮肤和其他局部用药)评估唇腭裂风险的比值比与研究的总体结果一致,没有显著的异质性,尽管与使用皮肤皮质类固醇相关的唇裂伴或不伴腭裂的 OR 为 1.45(95%CI 1.03-2.05)。
我们的结果增加了关于一类在怀孕期间常用药物的安全性信息。我们的研究没有显示皮质类固醇在怀孕期间的使用与唇腭裂风险增加之间存在关联。对唇腭裂与妊娠期间使用皮肤皮质类固醇之间的关联模式进行深入调查表明,这一结果并非表示因果关系,很可能源于多次统计学比较。